aspiration pneumonia general medicine rotation 12 15 09

ASPIRATION PNEUMONIATRENNETTE R. GILBERT, PHARM D. CANDIDATEUNIVERSITY OF SOUTHERN NEVADA COLLEGE OF PHARMACY

2

Objectives

Discuss background, epidemiology, and pathogenesis of aspiration pneumonia

Discuss risk factors for aspiration pneumonia

Discuss diagnosis, treatment, and monitoring response to therapy

Relate above objectives to patient case

3

Aspiration Pneumonia

Aspiration: inhalation of oropharyngeal or gastric contents into the larynx and lower respiratory tract Relatively common event Pneumonia is a consequence of aspiration

2 factors required for pneumonia to occur:1. Compromise of inherent defense mechanisms2. Bacterial burden must be large enough to cause infection

“True” aspiration pneumonia caused by normal flora Oral cavity Nasopharynx Gastrointestinal bacteria

4

Epidemiology

Incidence 2nd most frequent dx in hospitalized

Medicare patients Definition has not always been consistent

Etiology Most cases caused by anaerobes

CA: usually anaerobes alone HA: usually anaerobes + aerobes, polymicrobial

5

Risk factors for aspiration

Reduced consciousness Neurologic deficits GI disorders Anesthesia Protracted vomiting Large volume tube feedings

6

Signs/Symptoms

Predisposing condition for aspiration Putrid sputum Common pneumonia symptoms

Fever > 38°C Leukocytosis/leukopenia Productive cough Decline in oxygenation

7

Diagnosis

Suspect pneumonia if: New or progressive infiltrate seen on chest

x-ray AND signs/symptoms of systemic infection

Lower respiratory tract sampling Bronchoalveolar lavage or protected

specimen brush Culture specimen

8

Treatment

Treat hypoxemia/provide oxygen Empiric antibiotic selection depends on

setting/patient characteristics No clear guidelines on which regimen is best If nosocomial, more virulent bacteria s/b

targeted CA:

Respiratory FQ + clindamycin, metronidazole OR β-lactam/ β-lactamase inhibitor

HA: GNB coverage + clindamycin, metronidazole +/-

vancomycin

9

Monitoring Response to Therapy Vitals

Tmax, HR WBC

Should be trending down CXR

Should see improvement Oxygenation

Should see O2 sat increase Should be able to ↓ supportive oxygenation

10

Patient Case

AS is a 76 y/o male admitted to MOFH s/p hemicolectomy on 11/12.

Admitted to ICU for post-op observation and stabilization and subsequently transferred to SDU

On clear liquid diet → full liquid → soft diet 11/18: pt began to have episodes of emesis and

thick, discolored sputum 11/19: began to have increased work of

breathing 11/20: transferred to ICU and intubated.

S:

11

Patient Case cont…

PMH Near obstructing transverse colon malignancy Atrial fibrillation on warfarin Osteoarthritis of the hip w/ prosthesis HTN Iron deficiency anemia Diverticulosis Dyslipidemia

Allergies: Lortab, percocet, carvedilol

SH: (+) Tobacco, (-) alcohol, (-) IVDA

S:

12


Outpatient meds Furosemide 40 mg PO

BID Metoprolol tartrate 25

mg 1 and ½ tablets PO QD

Oxybutynin chloride 5 mg 1 PO QHS

Potassium Chloride 10 mEq PO BID

Simvastatin 80 mg PO QHS

Coumadin 2 mg as dir by anticoag clinic

Inpatient meds Protonix 40 mg IV

QD Heparin drip Digoxin 0.125 mg

IV QD Metoprolol 5 mg

IV Q4h Cardizem drip 5-

15 mg/hr Dilaudid PCA

O:

13


VS HR: 106-158 BP: 81/42 RR: 26 O2sat: 90% on 100% FIO2 NRB

Labs 7.199/46/71

Tmax: 102.3° F

137

4.3 16

109

2.1

66

158326

9.4

8.9

30.2

O:

14


ARDS 2° to aspiration pneumonia Septic shock ARF Post-op ileus

A:

15


Provide oxygenation Provide IV fluids Panculture Begin empiric antibiotics

P:

16


Antibiotics Vancomycin 1 gm Q 12h

Start: 11/22 Stop: 12/2 Metronidazole 500 mg IV Q6h

Start: 11/21 Stop: 12/1 Meropenem 1gm IV Q8h

Start: 11/25 Stop: 12/6 Fluconazole 400 mg IV QD

Start: 11/23 Stop: 11/30 Levofloxacin 500 mg IV QD

Start: 11/23 Stop: 12/6

17


Cultures Obtained 11/20

Blood No growth

Sputum Heavy growth E. coli and Klebsiella pneumoniae

Urine No growth

Stool (-) Salmonella, Shigella, Campylobacter

18


AS vitals Afebrile from 11/27 – 12/4 HR: 90s-130s

WBC After 7 days of abx therapy, began to trend down

CXR 11/22 – diffuse bilateral airspace opacities 11/24 – extensive bilateral pulmonary parenchymal

disease 11/30 – improving aeration of the lungs

Oxygenation On vent, required high FIO2 and PEEP set @ 15 By 11/28, FIO2 was able to ↓, now weaning off vent

19


AS risk factor for aspiration pneumonia: GI disorder: post-op ileus

AS symptoms consistent w/pneumonia: Productive cough, purulent sputum Decline in oxygenation Fever Chest x-ray abnormalities

20

Resolution

AS remains in ICU Still on vent, tolerating CPAP trials Awake, responsive Tolerating TF w/low residuals Developed DVTs

LUE, RLE Developed VAP and UTI

Both sputum and urine cultures grew Pseudomonas

21

Conclusions

AS treatment was appropriate Provided oxygen Empiric abx selection Corrected predisposing condition

My recommendations for aspiration pneumonia abx: CA:

Metronidazole + Levofloxacin HA:

Metronidazole + Meropenem + Aztreonam

References

1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005 171: 388-416.

2. Marik PE: Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001 Mar; 433(9): 655-71.

3. El-Solh et al: Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med, 2003 167:1650-54.

4. Koda-kimble5. Venes D, editor. Taber’s cyclopedic medical dictionary.

20th ed. Philadelphia: FA Davis Company; 2005. 1696 p.

aspiration pneumonia general medicine rotation 12 15 09

Health & Medicine